As of Jan 10, 2025, Regeneron Pharmaceuticals, Inc.'s Discounted Cash Flow (DCF) valuation estimates its share price at $1,149.0. This suggests it may be undervalued by 64.9% compared to its current price of around $696.9, using a WACC of 7.7% and growth rates of 3.0%.
As of Jan 10, 2025, Regeneron Pharmaceuticals, Inc.'s Weighted Average Cost of Capital (WACC) is approximately 7.7%.
As of Jan 10, 2025, Regeneron Pharmaceuticals, Inc.'s Enterprise Value (EV) is approximately $116.4B. This value reflects the company's total market capitalization plus debt, minus cash and cash equivalents, providing a comprehensive measure of its overall value in the market.